Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.41 |
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987029 | 0.97 | ERAP2 (0.55) | ERAP2ERAP1LNPEPSLC6A5CPB2 | |
| SCHEMBL30537467 | 0.92 | ERAP2 (0.53) | ERAP2ERAP1LNPEPSLC6A5CPB2 | |
| SCHEMBL23639482 | 0.89 | NMT1 (0.51) | ERAP2ERAP1LNPEPSLC6A5CPB2 | |
| SCHEMBL30957806 | 0.89 | FOLH1 (0.52) | ERAP2ERAP1LNPEPSLC6A5CPB2 | |
| SCHEMBL29915442 | 0.89 | TERT (0.50) | ERAP2ERAP1LNPEPSLC6A5CPB2 | |
| SCHEMBL27639948 | 0.88 | TERT (0.50) | ERAP2ERAP1LNPEPSLC6A5CPB2 | |
| SCHEMBL1674765 | 0.88 | TERT (0.50) | ERAP2ERAP1LNPEPSLC6A5CPB2 | |
| SCHEMBL31433376 | 0.86 | FOLH1 (0.46) | ERAP2ERAP1LNPEPSLC6A5CPB2 | |
| SCHEMBL30661446 | 0.86 | OPRD1 (0.53) | OPRD1OPRM1OPRK1FOLH1 | |
| SCHEMBL30661448 | 0.86 | OPRD1 (0.53) | OPRD1OPRM1OPRK1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | ERAP2 923/4885ERAP1 326/4885LNPEP 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.